Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for sibeprenlimab, an investigational monoclonal antibody developed to treat adults with immunoglobulin A nephropathy…
Empowering Patients Through Collaboration: Astellas’ Commitment to Pompe Disease Awareness This article shares real patient stories to raise awareness about Pompe disease. Individual experiences may differ. This content is for educational purposes only and should not be considered medical advice.…
Running from Friday through June 3 at McCormick Place Convention Center, the 2025 ASCO Annual Meeting promises to unveil pivotal data from a wide range of clinical trials. Experts suggest the findings could have far-reaching implications across oncology research and…
Health Canada has reaffirmed its commitment to safeguarding the country’s drug supply, stating it is “taking all necessary action” to ensure Canadians have continued access to essential prescription medications. This comes as the United States pushes forward with plans to…
Dr. Mark Stetter Joins Zoetis Board of DirectorsDean of the University of California, Davis School of Veterinary Medicine brings extensive and valuable experience in animal health to Zoetis Board (NYSE: ZTS) today announced the election of Dr. Mark Stetter to…
Roche and Broad Clinical Labs Partner to Advance Genomic Applications with SBX Sequencing Technology Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced a strategic collaboration with Broad Clinical Labs, aimed at exploring and developing innovative applications using Roche’s new Sequencing…
Eli Lilly to Present New Data on Imlunestrant, Olomorasib, LY4170156, and Verzenio® at 2025 ASCO Annual Meeting Eli Lilly and Company (NYSE: LLY) announced today that new clinical data from its oncology pipeline—including imlunestrant, olomorasib, LY4170156, and Verzenio® (abemaciclib)—will be…
New data from SEQUOIA, to be reported in two oral presentations, underscore the benefits of BRUKINSA® as first-line treatment for patients with chronic lymphocytic leukemia (CLL) Promising early phase data show the strength of the pipeline in treating multiple solid tumor…
The U.S. Bankruptcy Court of New Jersey approved CVS Pharmacy® bids on the prescription files of 625 Rite Aid pharmacies across 15 states in areas that CVS serves, as well 64 Rite Aid stores in Idaho, Oregon and Washington. The transaction…
Johnson & Johnson MedTech Launches SOUNDSTAR CRYSTAL™ Ultrasound Catheter in the U.S. to Enhance Cardiac Ablation Procedures May 2025 – Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, has announced the U.S. launch of the SOUNDSTAR CRYSTAL™…
Access to Obesity Medications Shouldn’t Be This Hard Recent changes in insurance coverage have forced thousands of Americans living with obesity into an impossible choice: stop taking a safe, effective medication recommended by their health care provider—or pay out of…
Eli Lilly’s Kisunla Receives Regulatory Approval in Australia for Early Alzheimer’s Treatment Eli Lilly and Company (NYSE: LLY) announced today that Australia’s Therapeutic Goods Administration (TGA) has granted marketing authorization for Kisunla (donanemab), an intravenous infusion therapy administered every four…